Aeglea Appoints Sandy Mahatme And Russell Cox To Board Of Directors

AUSTIN, Texas--(BUSINESS WIRE)--Aeglea Biotherapeutics, Inc., a biopharmaceutical company committed to developing enzyme based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the appointment of Sandy Mahatme and Russell Cox to its Board of Directors. Mr. Mahatme currently serves as Senior Vice President, Chief Financial Officer for Sarepta Therapeutics, and Mr. Cox serves as Executive Vice President and Chief Operating Officer for Jazz Pharmaceuticals.